Although the new KRASG12C-targeted small molecule (G12Ci) has the ability to inhibit KRAS signaling and generate objective responses in this patient population, only a minority of KRASG12C NSCLC patients have responded to these treatments. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.